Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing

Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing

On-Demand Webcast

Axel Grothey, MD
West Cancer Center
Memphis, Tennessee


Ghassan K. Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic
Scottsdale, Arizona

Pashtoon M. Kasi, MD, MS
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa

Target Audience

This activity is intended for community and academic clinicians who treat or are interested in treating patients with GI malignancies, including community oncologists and other HCPs (physicians-in-training, oncology nurses, pharmacists, physician assistants, and others) involved in the therapeutic management of patients with GI cancers.


Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. HCC is the ninth leading cause of cancer deaths in the United States. Patient outcomes and treatment decisions are highly dependent on HCC stage and severity at diagnosis. The advent of new targeted agents has finally led to choice in treatment options. Although these advances are a welcome addition to the therapeutic armamentarium, their emergence creates a clinical conundrum in understanding their pharmacologic profiles, identifying appropriate patients that may benefit from these treatments, how to manage their unique side effects, and how best to integrate these agents into patient-centered sequencing decisions.

This webcast aims to guide learners to understand challenges associated with new therapeutic targets in HCC and identify strategies to manage adverse events and side effects.


Upon successful completion of this educational activity, participants should be better able to:

  1. Describe the clinical and societal burden of advanced HCC and the challenges with the application of guideline-directed systemic therapy
  2. Discuss the successes and challenges associated with identifying therapeutic targets in HCC and the available clinical data in support of new and emerging agents
  3. Identify strategies to mitigate/manage the unique side effects associated with targeted therapies for HCC
  4. Incorporate the latest evidence-based guidance, therapeutic advances, and clinical data into optimal, patient-centered HCC sequencing strategies

Release Date: October 31, 2019

Expiration Date: October 31, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by educational grants from: Bayer HealthCare Pharmaceuticals, Exelixis, Inc., Genentech, Inc., and Merck Sharp & Dohme Corp.


 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


NACCME designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 0.75 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.75 contact hours.


This knowledge-based activity (JA0006201-9999-20-014-H01-P) is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Ghassan K. Abou-Alfa, MD, MBA, Tanios Bekaii-Saab, MD, FACP, Axel Grothey, MD, Pashtoon M. Kasi, MD, MS; and Chris Bolwell, and Manjusha Sala, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Ghassan K. Abou-Alfa, MD, MBA, reports that he is a consultant for 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Jansen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Novella, Onxeo, PCI Biotech, Pfizer, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vicus, Yakult, and Yiviva.

Tanios Bekaii-Saab, MD, FACP, reports that he is a consultant for AbbVie, Armo, Immuneering, Imugene, and Silajen.

Axel Grothey, MD, reports that he is a consultant for ARRAY, AG from Bayer, Boston Biomedicals, BMS, Daiichi, and Genentech/Roche; and has received grant or research support from Bayer, Boston Biomedicals, BMS, Daiichi, and Genentech/Roche.

Pashtoon M. Kasi, MD, MS, reports that he is a consultant for Ipsen; and has received grant or research support from AAA, Array, BMS, and Celgene.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Manjusha Sala disclosed no relevant financial relationships with any commercial interests.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.